Hashimoto's Thyroiditis (Investigational Cervical Adjunct)
Highly investigational adjunct in stable Hashimoto's thyroiditis; small uncontrolled series only; levothyroxine replacement remains primary.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for Hashimoto thyroiditis. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
- What evidence exists?
- Tier C (investigational). No controlled trials have been identified; two small uncontrolled reports (a 1997 Russian series including 18 patients with autoimmune thyroiditis, and a 2025 Azerbaijani series of 18 patients with thyroiditis of unspecified type) describe improvement after leech application, without a comparison group. Evidence-based first-line management is levothyroxine replacement when hypothyroidism is biochemically confirmed (TSH above the reference range with low free T4, or TSH consistently above 10). Subclinical disease may be observed. Selenium has marginal evidence for reducing antibody titers but does not change long-term outcomes.
- Main risks
- Bleeding from each bite site for 6 to 10 hours after the leech detaches
- Iron-deficiency anemia from cumulative blood loss across multiple sessions
- Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
- Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
- Small Y-shaped bite marks or skin colour changes at the bite sites, which usually fade over weeks to months
- Local pain, bruising, swelling, or itching for 1 to 3 days after each session
- Who should not consider this
- Patients with TSH greater than 10 or clearly symptomatic hypothyroidism (need levothyroxine, not leeches)
- Patients planning to defer or stop thyroid hormone replacement based on leech treatment
- Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran or heparin (daily aspirin alone is not a contraindication: tell your doctor, who starts with fewer leeches)
- People with hemophilia or any other inherited bleeding disorder
- Patients with anemia
- People with an active infection at the planned application site
- Patients who are pregnant (leech therapy is not done during pregnancy) or breastfeeding (discuss it with your doctor)
- What to ask your clinician
- Is my hypothyroidism mild enough that observation is appropriate, or do I need levothyroxine?
- Will the leech therapy delay or replace any needed thyroid hormone replacement (it should not)?
- How will thyroid function be monitored during the course?
- What is the published evidence base for leeches and autoimmune thyroiditis specifically?
- Could pregnancy be in my future, and how does that affect thyroid management?
- What is your plan if my thyroid antibodies do not change?
- When to seek urgent care
- Bleeding from a bite site that soaks through more than one dressing per hour
- Bleeding that continues more than 24 hours after the leech detached
- Spreading redness, warmth, swelling, pus, or red streaks around any bite site
- Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
- Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
- Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
- Severe fatigue, cold intolerance, slow heart rate, or confusion (worsening hypothyroidism)
- Rapid neck swelling, difficulty swallowing or breathing (rare painful thyroiditis variant)
What this does NOT mean
- It does not mean leech therapy is FDA-cleared for Hashimoto thyroiditis — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
- It does not replace levothyroxine replacement when hypothyroidism is biochemically present.
- No study has shown that it lowers antithyroid antibodies or stops the underlying autoimmune process.
- It does not have controlled-trial evidence in Hashimoto disease.
- No study has examined its effect on long-term progression to clinical hypothyroidism.
Safety cross-references
Clinical Profile
- Category
- Other
- ICD-10
- E06.3
- Safety tier
- High
Evidence Summary
Hashimoto's thyroiditis is managed with levothyroxine replacement to normalize TSH per ATA 2014 guidelines, and subclinical hypothyroidism is treated based on age, TSH level, antibody status, and symptoms. No controlled clinical trial of leech therapy for Hashimoto's thyroiditis was identified in PubMed, Europe PMC or ClinicalTrials.gov. Two small uncontrolled series have been reported: a Russian series (Konstantinova 1997, summarized in the Baskova and Isakhanyan 2004 monograph) of 18 patients with chronic autoimmune thyroiditis, 13 of whom were reported improved, and an Azerbaijani clinic series (Farzali 2025) of 18 patients with thyroiditis of unspecified type, 17 of whom were rated successful by patient and physician judgement. Neither had a control group, so the honest evidence grade is D; use is investigational and any local anti-inflammatory rationale is speculative. Leech placement is anatomically risky given carotid proximity and cannot be recommended outside of a research setting.
What the books describe
Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.
- Baskova and Isakhanyan give a list of diseases for which, with reference to published reports, treatment with leeches is recommended; in the section “In endocrinology” they name autoimmune thyroiditis and diffuse toxic goiter (the word “Hashimoto” does not appear in their book; the disease is called autoimmune thyroiditis)[B1].
- They retell an observation by Konstantinova and colleagues (1997): among 22 patients treated with hirudotherapy for thyroid diseases, 18 had chronic autoimmune thyroiditis; according to the description, improvement occurred in 13 patients with this thyroiditis, and improvement was judged by clinical examination and by normalization of the size and function of the gland (hormonal status and ultrasound examination)[B1].
- The same paragraph contains a sentence saying that the safety of the procedures, the absence of complications, their cost-effectiveness and availability make it possible to recommend leeches for treating thyroid diseases; whose assessment this is, that of the authors of the study or of the authors of the book, is not clear from the text; no comparison group or follow-up period is named, and in the reference list the study is titled “Hirudoreflexotherapy in the Comprehensive Treatment of Thyroid Diseases,” and what else was part of the treatment is not clear from the text[B1].
- For another thyroid disease, subacute thyroiditis, Baskova and Isakhanyan cite a comparison by Vedeneeva and Medvedeva (2000): in 8 patients leeches were added to the usual treatment, and 10 patients were treated with the usual methods only; according to the description, in the former the pain and the size and consistency of the gland decreased already on the first day and there were no relapses, whereas in the latter the effect came after a month or later; how the patients were assigned to the groups and how long they were followed is not stated[B1].
- Baskova and Isakhanyan criticize the work of other authors in which, as they retell it, one patient with autoimmune thyroiditis was prescribed a very large number of leeches over a long period, and they write that the results of these studies cannot be taken seriously; in the chapter on indications and contraindications they add that, so as not to harm the patient, a dosed use should be followed, and that prescribing leeches in large numbers, for long periods, without breaks or with short breaks is unjustified and unacceptable[B1].
- Among the contraindications listed in the book by Baskova and Isakhanyan (their list is longer) are hemophilia, hemorrhagic diatheses, anemias and the simultaneous use of anticoagulants; Michalsen et al. (chapter 8, “Contraindications,” Flecken and Michalsen) call hemophilia and the use of anticoagulants an absolute contraindication, and in anemia, in their words, treatment involving blood loss is generally contraindicated[B1][B3].
- Michalsen et al. (in the same chapter 8) write that leech therapy should never be performed in patients with severe, unstable organic disease or marked immunosuppression (for example, chemotherapy), while severe chronic but stable organ diseases, among them “immune diseases” and connective tissue diseases, are classed as relative contraindications; they do not name autoimmune thyroiditis, and whether such patients count as having “immune diseases” is not clear from the book[B3].
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)
Key Trials
- Farzali S et al. (2025), n=18 · Turkiye Parazitol Derg · PMID 40923484 · ASH analysis →
Contraindications
- Hemophilia or another bleeding disorder
- Taking anticoagulants (blood thinners such as warfarin or heparin)
- Anemia or suppressed blood formation
- Low blood pressure, shock, collapse or fainting
- Severe wasting (cachexia)
- Intolerance of leeches or a history of severe allergic reactions
- Pregnancy
- Stomach or duodenal ulcer, erosive gastritis
- Acute infectious disease or high fever
- Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
- Drinking alcohol at the time of treatment
- No consent from the patient
- Compressive goiter or large nodules requiring biopsy
- Suspicion of thyroid malignancy
- Active Graves disease or thyroid storm
- Carotid disease or recent neck surgery
- Anticoagulation for atrial fibrillation
Related Conditions
Thyroid Eye Disease (Investigational Periocular Adjunct)
Highly investigational periocular adjunct for stable thyroid eye disease; ocular risk is critical; teprotumumab and orbital decompression remain primary.
Metabolic Syndrome (Investigational Adjunct)
Investigational adjunct to lifestyle modification in metabolic syndrome; no clinical study in metabolic syndrome identified; weight loss, dietary modification, and pharmacotherapy remain primary.
Recurrent Aphthous Stomatitis (Investigational Adjunct)
Investigational adjunct for severe recurrent aphthous stomatitis; topical corticosteroids, chlorhexidine, and (for severe disease) colchicine or systemic immunomodulators remain evidence-based.
Chronic Postsurgical Pain Syndrome (Investigational Adjunct)
Investigational adjunct for chronic postsurgical pain after surgical site healed; multimodal pain management including pharmacotherapy, physical therapy, and (for neuropathic features) interventional pain procedures remain evidence-based.
References
- [B1]
Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]
Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.
- [B3]
Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy
ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.
The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.